Experimental Drug Zoliflodacin Emerges as Potential Game Changer in Fight Against Super Gonorrhea

Large-scale clinical trial shows zoliflodacin, developed by Global Antibiotic Research & Development Partnership and Entasis Therapeutics, to be as effective as frontline antibiotics in treating super gonorrhea, providing hope against antibiotic resistance.

• Zoliflodacin, an experimental drug, has been found to be as effective as frontline antibiotics in treating super gonorrhea. It has the potential to be particularly effective against antibiotic-resistant strains of the STI.
• In a large-scale clinical trial with over 900 participants, a single oral dose of zoliflodacin was compared to a combination of two antibiotics commonly used for treating gonorrhea. The trial met its primary goal, with zoliflodacin clearing the infection as effectively as the established treatment.
• Developed by the Global Antibiotic Research & Development Partnership and Entasis Therapeutics, zoliflodacin uses a novel mechanism to kill gonorrhea bacteria, extending the potential duration of its effectiveness before resistance develops.
• Zoliflodacin is expected to be commercialized widely. Its distribution rights have already been obtained for most low-to-middle income countries. The aim is to make the drug affordable and only use it when other treatments fail, in order to prolong its resistance.

3 Articles

Gizmodo NBC News Washington Post